Which has stronger earnings & valuation, BHVN or ENTX?

Entera Bio has higher revenue and earnings than Biohaven. Entera Bio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Entera Bio $40K 11,022.18 -$11.44M -$0.35 N/A

Is BHVN or ENTX more profitable?

Entera Bio's return on equity of -147.19% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Entera Bio N/A -147.19% -103.22%

Does the media prefer BHVN or ENTX?

In the previous week, Biohaven and Biohaven both had 5 articles in the media. Biohaven's average media sentiment score of 0.33 beat Entera Bio's score of 0.05 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SEPN or ENTX?

Entera Bio has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $45.95M 37.00 -$48.88M -$0.54 N/A Entera Bio $40K 10,826.52 -$11.44M -$0.35 N/A

Is SEPN or ENTX more profitable?

Entera Bio has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -24.51% -9.57% -6.28% Entera Bio N/A -147.19% -103.22%

Does the media favor SEPN or ENTX?

In the previous week, Entera Bio had 2 more articles in the media than Septerna. MarketBeat recorded 5 mentions for Entera Bio and 3 mentions for Septerna. Septerna's average media sentiment score of 1.09 beat Entera Bio's score of 0.04 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ENTX or NTLA?

In the previous week, Intellia Therapeutics had 6 more articles in the media than Entera Bio. MarketBeat recorded 11 mentions for Intellia Therapeutics and 5 mentions for Entera Bio. Intellia Therapeutics' average media sentiment score of 0.69 beat Entera Bio's score of 0.04 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ENTX or NUVB?

Entera Bio has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio $40K 10,826.52 -$11.44M -$0.35 N/A Nuvation Bio $62.90M 26.38 -$204.63M -$0.44 N/A

Is ENTX or NUVB more profitable?

Entera Bio has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Nuvation Bio -88.18% -46.59% -22.01%

Does the media prefer ENTX or NUVB?

In the previous week, Entera Bio had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 5 mentions for Entera Bio and 3 mentions for Nuvation Bio. Entera Bio's average media sentiment score of 0.04 beat Nuvation Bio's score of -0.18 indicating that Entera Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ENTX or ZBIO more profitable?

Zenas BioPharma's return on equity of -122.45% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Zenas BioPharma N/A -122.45% -58.04%

Does the media prefer ENTX or ZBIO?

In the previous week, Zenas BioPharma had 10 more articles in the media than Entera Bio. MarketBeat recorded 15 mentions for Zenas BioPharma and 5 mentions for Entera Bio. Zenas BioPharma's average media sentiment score of 0.36 beat Entera Bio's score of 0.04 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 1 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Entera Bio (ENTX) Competitors

$2.51 +0.02 (+0.68%)

As of 03:27 PM Eastern

Compare

ENTX vs. BHVN, SEPN, NTLA, NUVB, and ZBIO

Should you buy Entera Bio stock or one of its competitors? Entera Bio's main competitors and comparable companies include Biohaven (BHVN), Septerna (SEPN), Intellia Therapeutics (NTLA), Nuvation Bio (NUVB), and Zenas BioPharma (ZBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Entera Bio compare to Biohaven?

Biohaven (NYSE:BHVN) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Biohaven presently has a consensus price target of $18.69, suggesting a potential upside of 69.89%. Entera Bio has a consensus price target of $9.60, suggesting a potential upside of 278.70%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts clearly believe Entera Bio is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Biohaven has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

88.8% of Biohaven shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Comparatively, 10.6% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Biohaven and Biohaven both had 5 articles in the media. Biohaven's average media sentiment score of 0.33 beat Entera Bio's score of 0.05 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entera Bio has higher revenue and earnings than Biohaven. Entera Bio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Entera Bio	$40K	11,022.18	-$11.44M	-$0.35	N/A

Entera Bio's return on equity of -147.19% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Entera Bio	N/A	-147.19%	-103.22%

Summary

Entera Bio beats Biohaven on 8 of the 14 factors compared between the two stocks.

How does Entera Bio compare to Septerna?

Septerna (NASDAQ:SEPN) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Septerna has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

In the previous week, Entera Bio had 2 more articles in the media than Septerna. MarketBeat recorded 5 mentions for Entera Bio and 3 mentions for Septerna. Septerna's average media sentiment score of 1.09 beat Entera Bio's score of 0.04 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Septerna currently has a consensus price target of $52.44, indicating a potential upside of 44.00%. Entera Bio has a consensus price target of $9.60, indicating a potential upside of 285.54%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts clearly believe Entera Bio is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Entera Bio has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	37.00	-$48.88M	-$0.54	N/A
Entera Bio	$40K	10,826.52	-$11.44M	-$0.35	N/A

Entera Bio has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
Entera Bio	N/A	-147.19%	-103.22%

14.1% of Entera Bio shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 10.6% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Entera Bio beats Septerna on 10 of the 16 factors compared between the two stocks.

How does Entera Bio compare to Intellia Therapeutics?

Entera Bio (NASDAQ:ENTX) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Entera Bio has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

Entera Bio has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

In the previous week, Intellia Therapeutics had 6 more articles in the media than Entera Bio. MarketBeat recorded 11 mentions for Intellia Therapeutics and 5 mentions for Entera Bio. Intellia Therapeutics' average media sentiment score of 0.69 beat Entera Bio's score of 0.04 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entera Bio has higher earnings, but lower revenue than Intellia Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	10,826.52	-$11.44M	-$0.35	N/A
Intellia Therapeutics	$67.67M	24.66	-$412.69M	-$3.36	N/A

Entera Bio presently has a consensus price target of $9.60, indicating a potential upside of 285.54%. Intellia Therapeutics has a consensus price target of $20.72, indicating a potential upside of 73.95%. Given Entera Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Entera Bio is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Intellia Therapeutics	5 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.26

Summary

Intellia Therapeutics beats Entera Bio on 8 of the 15 factors compared between the two stocks.

How does Entera Bio compare to Nuvation Bio?

Entera Bio (NASDAQ:ENTX) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Entera Bio has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	10,826.52	-$11.44M	-$0.35	N/A
Nuvation Bio	$62.90M	26.38	-$204.63M	-$0.44	N/A

Entera Bio has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Entera Bio has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Nuvation Bio	-88.18%	-46.59%	-22.01%

In the previous week, Entera Bio had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 5 mentions for Entera Bio and 3 mentions for Nuvation Bio. Entera Bio's average media sentiment score of 0.04 beat Nuvation Bio's score of -0.18 indicating that Entera Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entera Bio currently has a consensus target price of $9.60, suggesting a potential upside of 285.54%. Nuvation Bio has a consensus target price of $13.22, suggesting a potential upside of 179.84%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts clearly believe Entera Bio is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Entera Bio beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.

How does Entera Bio compare to Zenas BioPharma?

Entera Bio (NASDAQ:ENTX) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Zenas BioPharma's return on equity of -122.45% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Zenas BioPharma	N/A	-122.45%	-58.04%

14.1% of Entera Bio shares are held by institutional investors. 10.6% of Entera Bio shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Entera Bio currently has a consensus price target of $9.60, suggesting a potential upside of 285.54%. Zenas BioPharma has a consensus price target of $46.71, suggesting a potential upside of 85.67%. Given Entera Bio's stronger consensus rating and higher possible upside, analysts plainly believe Entera Bio is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Zenas BioPharma had 10 more articles in the media than Entera Bio. MarketBeat recorded 15 mentions for Zenas BioPharma and 5 mentions for Entera Bio. Zenas BioPharma's average media sentiment score of 0.36 beat Entera Bio's score of 0.04 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entera Bio has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market.

Entera Bio has higher earnings, but lower revenue than Zenas BioPharma. Entera Bio is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	10,826.52	-$11.44M	-$0.35	N/A
Zenas BioPharma	$10M	163.99	-$377.74M	-$8.99	N/A

Summary

Entera Bio beats Zenas BioPharma on 8 of the 15 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTX vs. The Competition

Export

Metric	Entera Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$434.80M	$3.90B	$7.29B	$12.91B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-7.14	12.96	275.68	25.25
Price / Sales	10,900.44	1,151.37	562.78	78.51
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	8.64	16.59	10.54	5.92
Net Income	-$11.44M	-$22.69M	$3.50B	$381.16M
7 Day Performance	-0.12%	-6.38%	-4.13%	-4.32%
1 Month Performance	-11.10%	-14.15%	-8.51%	-7.19%
1 Year Performance	-1.30%	6.41%	2.12%	-4.99%

Entera Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTX Entera Bio	2.9204 of 5 stars	$2.51 +0.7%	$9.60 +282.9%	-7.8%	$434.80M	$40K	N/A	21	News Coverage Short Interest Increase
BHVN Biohaven	3.3977 of 5 stars	$11.46 -3.0%	$18.69 +63.1%	-25.1%	$1.73B	N/A	N/A	274
SEPN Septerna	2.5344 of 5 stars	$36.42 -3.0%	$52.44 +44.0%	+51.2%	$1.70B	$45.95M	N/A	130	Positive News
NTLA Intellia Therapeutics	3.3228 of 5 stars	$11.91 -5.3%	$20.72 +73.9%	-49.9%	$1.67B	$67.67M	N/A	377
NUVB Nuvation Bio	2.299 of 5 stars	$4.73 -3.6%	$13.22 +179.8%	+28.2%	$1.66B	$62.90M	N/A	305

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entera Bio (ENTX) Competitors

ENTX vs. BHVN, SEPN, NTLA, NUVB, and ZBIO

How does Entera Bio compare to Biohaven?

Summary

How does Entera Bio compare to Septerna?

Summary

How does Entera Bio compare to Intellia Therapeutics?

Summary

How does Entera Bio compare to Nuvation Bio?

Summary

How does Entera Bio compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entera Bio (ENTX) Competitors

ENTX vs. BHVN, SEPN, NTLA, NUVB, and ZBIO

How does Entera Bio compare to Biohaven?

Do analysts prefer BHVN or ENTX?

Which has more risk & volatility, BHVN or ENTX?

Do insiders & institutionals hold more shares of BHVN or ENTX?

Does the media prefer BHVN or ENTX?

Which has stronger earnings & valuation, BHVN or ENTX?

Is BHVN or ENTX more profitable?

Summary

How does Entera Bio compare to Septerna?

Which has more risk & volatility, SEPN or ENTX?

Does the media favor SEPN or ENTX?

Do analysts recommend SEPN or ENTX?

Which has higher valuation & earnings, SEPN or ENTX?

Is SEPN or ENTX more profitable?

Do insiders & institutionals believe in SEPN or ENTX?

Summary

How does Entera Bio compare to Intellia Therapeutics?

Do insiders and institutionals believe in ENTX or NTLA?

Which has more volatility & risk, ENTX or NTLA?

Is ENTX or NTLA more profitable?

Does the media refer more to ENTX or NTLA?

Which has better valuation & earnings, ENTX or NTLA?

Do analysts recommend ENTX or NTLA?

Summary

How does Entera Bio compare to Nuvation Bio?

Do institutionals and insiders hold more shares of ENTX or NUVB?

Which has better earnings and valuation, ENTX or NUVB?

Which has more volatility & risk, ENTX or NUVB?

Is ENTX or NUVB more profitable?

Does the media prefer ENTX or NUVB?

Do analysts recommend ENTX or NUVB?

Summary

How does Entera Bio compare to Zenas BioPharma?

Is ENTX or ZBIO more profitable?

Do insiders & institutionals have more ownership in ENTX or ZBIO?

Do analysts prefer ENTX or ZBIO?

Does the media prefer ENTX or ZBIO?

Which has more risk and volatility, ENTX or ZBIO?

Which has better valuation & earnings, ENTX or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools